tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATYR Stock Latest News

aTyr Pharma price target raised to $17 from $9 at Jefferies
The FlyaTyr Pharma price target raised to $17 from $9 at Jefferies
15h ago
ATYR
Optimistic Buy Rating for aTyr Pharma Amid Promising EFZO-FIT Trial Prospects
PremiumRatings
Optimistic Buy Rating for aTyr Pharma Amid Promising EFZO-FIT Trial Prospects
21h ago
ATYR
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study
PremiumRatings
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study
8d ago
ATYR
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach
PremiumRatings
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach
11d ago
ATYR
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma
PremiumRatings
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma
14d ago
ATYR
aTyr Pharma: Strong Financials and Promising Therapeutic Candidate Drive Buy Rating
PremiumRatingsaTyr Pharma: Strong Financials and Promising Therapeutic Candidate Drive Buy Rating
15d ago
ATYR
aTyr Pharma Reports Q2 2025 Financial Results
Premium
Company Announcements
aTyr Pharma Reports Q2 2025 Financial Results
15d ago
ATYR
aTyr Pharma files $300M mixed securities shelf
Premium
The Fly
aTyr Pharma files $300M mixed securities shelf
15d ago
ATYR
aTyr Pharma reports Q2 EPS (22c), consensus (18c)
PremiumThe Fly
aTyr Pharma reports Q2 EPS (22c), consensus (18c)
15d ago
ATYR
aTyr Pharma Inc put volume heavy and directionally bearish
PremiumThe Fly
aTyr Pharma Inc put volume heavy and directionally bearish
16d ago
ATYR
Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
PremiumRatings
Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
22d ago
ATYR
aTyr Pharma Inc put volume heavy and directionally bearish
PremiumThe Fly
aTyr Pharma Inc put volume heavy and directionally bearish
25d ago
ATYR
aTyr Pharma management to meet with Cantor Fitzgerald
PremiumThe FlyaTyr Pharma management to meet with Cantor Fitzgerald
25d ago
ATYR
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
Premium
Ratings
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
1M ago
ATYR
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
Premium
Ratings
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
1M ago
ATYR
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study
PremiumThe Fly
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study
1M ago
ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
PremiumRatings
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
1M ago
ATYR
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
PremiumRatings
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
2M ago
ATYR
aTyr Pharma to be added to Russell 2000, Russell 3000 Indices
PremiumThe Fly
aTyr Pharma to be added to Russell 2000, Russell 3000 Indices
2M ago
ATYR
aTyr Pharma price target raised to $25 from $17 at Wells Fargo
PremiumThe FlyaTyr Pharma price target raised to $25 from $17 at Wells Fargo
2M ago
ATYR
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
Premium
Ratings
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
3M ago
ATYR
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
Premium
Ratings
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
3M ago
ATYR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >